New e-book explores transformative medtech advancements in
pulsed field ablation for atrial fibrillation treatment
LONDON, Feb. 4, 2025
/PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global
provider of transformative intelligence and BioWorld by Clarivate,
today published a new e-book, Pulsed field ablation: stunning
growth shocks the atrial fibrillation market. The Clarivate
e-book highlights new medtech breakthroughs in the pulsed field
ablation (PFA) market, forecasting its future growth and showcasing
the technology's potential to transform the treatment paradigm for
atrial fibrillation.
Cryoablation and radiofrequency (RF) ablation can cause damage
to non-targeted tissues, such as the pulmonary vein, esophagus and
phenic nerve. As a result, PFA has emerged as an appealing
alternative for treating atrial fibrillation, attracting
significant investment from companies worldwide. The technology
leverages high-voltage, microsecond electrical pulses rather than
thermal energy, enabling a safer, faster procedure with higher
success rates and reduced recurrence rates. Consequently,
electrophysiologists are rapidly switching to PFA and away from RF
and cryoablation.
Juliane Ray, General Manager,
Medtech, Life Sciences and Healthcare, Clarivate, said: "The
evolution of cardiac ablation is at a pivotal moment, with pulsed
field ablation emerging as a breakthrough that is reshaping
treatment guidelines and expanding patient access worldwide. As
clinical evidence continues to build, we are seeing a shift toward
ablation as a first-line therapy, reinforcing the need for
innovation in mapping, delivery systems, and procedural efficiency.
This e-book explores the latest advancements and market dynamics,
equipping stakeholders with the insights needed to anticipate the
next wave of transformation in cardiac care."
Andrew Lee, Vice President,
Medtech, Life Sciences and Healthcare, Clarivate,
said: "The rapid adoption of pulsed field ablation
underscores its transformative potential in cardiac care, reshaping
the treatment landscape and expanding access for patients
worldwide. This e-book provides cardiologists and medical device
companies with a comprehensive view of the latest advancements and
trends, equipping them with the insights needed to navigate this
evolving market. As PFA drives unprecedented growth and innovation,
staying informed is crucial for making strategic decisions that
align with this dynamic and rapidly expanding sector."
Anette Boyle, Editor,
BioWorld, Clarivate, said: "PFA may be the most significant
Medtech advance in cardiology in the last decade – and it has
certainly been the most rapidly adopted. With the total number of
cardiac ablation procedures for atrial fibrillation expected to
double in the next two to three years, major players and start-ups
alike are racing to complete clinical trials and gain regulatory
approvals. We expect to see brisk M&A in this area as companies
lagging in development of their own products seek to leapfrog the
competition and secure a slice of this hot market."
Key updates and the forecast of the global PFA market
featured in Pulsed field ablation: stunning growth shocks
the atrial fibrillation market, include:
- Key players: Companies and PFA systems, including
FARAPULSE, Affera Sphere-9 and PulseSelect, gained regulatory
approvals around the world and even more began clinical trials in
2024. While Johnson & Johnson's VARIPULSE received FDA approval
in November, the company indefinitely paused its limited U.S.
rollout to investigate multiple neurovascular events associated
with its use in January. Abbott Laboratories, the last of the big
four players in the market to gain U.S. marketing authorization,
completed enrolment in its VOLT-AF pivotal trial in October and
could receive FDA approval as early as mid-2026, with CE mark
likely in early 2025.
- Rapid expansion in international markets: PFA
adoption grew exponentially with FDA approvals in the U.S. in late
2023 and early 2024. Mainland China, Japan
and Australia all have three
approved PFA systems, and the market for PFA in the Asia Pacific region is expected to surpass
$1 billion over the next three to
five years. China has several
domestic manufacturers in the mix, making it a more competitive
landscape for global firms. Japan
alone could become a $300 million
market by 2028.
- Market value forecast: From a base of $300 million globally in 2023 and 5% of the
atrial fibrillation market, Clarivate expects PFA to approach
$8 billion in market value and
capture more than 70% of the global atrial fibrillation market by
2028.
Pulsed Field Ablation: Stunning Growth Shocks the Atrial
Fibrillation Market, offers an in-depth analysis of recent
breakthroughs and the transformative potential of PFA technology
featuring insights from the editor of BioWorld MedTech,
Annette Boyle, and up-to-the-minute
analysis from Clarivate's Medtech experts.
To learn more about the Clarivate e-book, visit here.
To track developments in cardiac ablation and other medical
technologies on a daily basis, subscribe to BioWorld MedTech, here:
BioWorld MedTech: The Daily Medical Technology News Source.
The Electrophysiology Mapping and Ablation Device
Market Insights series provides a comprehensive global market
view with granular insights into market dynamics in the broader
ablation market as well as the game-changing potential of PFA
technology. Designed to ensure our customers have the most current
and actionable data to guide their strategic decisions and drive
progress toward a healthier future, the series draws on the
expertise of Clarivate's Medtech analysts, who leverage proprietary
Clarivate Medtech Intelligence data, including Real World
Data assets like claims data and PriceTrack. For the
latest forecasts for Electrophysiology Mapping and Ablation
Device geographical markets, see our Medtech Insights reports,
here: Medtech Insights | Clarivate
About BioWorld
With writers and editors stationed
around the globe, BioWorld MedTech, published by Clarivate, reports
the breaking news and provides key perspective on thousands of
innovative medical technologies and devices in development, the
companies behind those candidates, the business development
transactions that evolve the markets, and the regulatory hurdles
that both challenge and guard the processes. The
BioWorld group of news services (BioWorld, BioWorld Science,
BioWorld MedTech and BioWorld Asia) has a long tradition of
excellence in journalism. Collectively, the news services have been
honored with 70 awards dating back to 1998.
About Clarivate
Clarivate is a leading global provider of transformative
intelligence. We offer enriched data, insights & analytics,
workflow solutions and expert services in the areas of Academia
& Government, Intellectual Property and Life Sciences &
Healthcare. For more information, please
visit www.clarivate.com
Media Contact:
Luna
Ivkovic,
External Communications, Life Sciences & Healthcare
newsroom@clarivate.com
Logo -
https://mma.prnewswire.com/media/1159266/Clarivate_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/clarivate-reveals-medtech-breakthroughs-driving-growth-in-pulsed-field-ablation-market-302366557.html
